Pavlova A, Krupa J C, Mort J S, Abrahamson M, Björk I
The Biomedical Center, Department of Veterinary Medical Chemistry, Swedish University of Agricultural Sciences, Uppsala, Sweden.
FEBS Lett. 2000 Dec 29;487(2):156-60. doi: 10.1016/s0014-5793(00)02337-1.
Cystatins A and C were both shown to inhibit cathepsin B by a two-step mechanism, involving an initial weak interaction followed by a conformational change. Disruption of the major salt bridge anchoring the occluding loop of cathepsin B to the main body of the enzyme by mutation of His110 to Ala converted the binding to an apparent one-step reaction. The second step of cystatin binding to cathepsin B must therefore be due to the inhibitor having to alter the conformation of the enzyme by displacing the occluding loop to allow a tight complex to be formed. Cystatin A was appreciably less effective in displacing the loop than cystatin C, resulting in a considerably lower overall inhibition rate constant.
胱抑素A和C均通过两步机制抑制组织蛋白酶B,该机制包括初始的弱相互作用,随后是构象变化。通过将组氨酸110突变为丙氨酸,破坏了将组织蛋白酶B的封闭环锚定到酶主体的主要盐桥,使结合转变为明显的一步反应。因此,胱抑素与组织蛋白酶B结合的第二步必定是由于抑制剂必须通过取代封闭环来改变酶的构象,以形成紧密复合物。在取代封闭环方面,胱抑素A的效果明显低于胱抑素C,导致总体抑制速率常数显著降低。